8 completed. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE) Buprenorphine Transdermal Matrix Patch, Sham patch - Opioid Use Disorder, Pregnancy Related | Phase 3 | Completed | Washington University School of Medicine | 7 | 2023-11-27 | 2026-09-10 |
| Mobile & Online-Based Interventions to Lessen Pain Empowered Relief On-Demand, Health Education - Chronic Pain, Opioid Misuse | Phase 3 | Completed | Stanford University | 234 | 2023-08-23 | 2025-12-18 |
| Open-Label Treatment Extension Study RBP-6000 - Opioid Use Disorder, Opioid-related Disorders | Phase 3 | Completed | Indivior Inc. | 208 | 2016-08-17 | 2018-11-29 |
| Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL Naltrexone, Placebo, Buprenorphine - Opioid Use Disorder | Phase 3 | Completed | Alkermes, Inc. | 101 | 2016-04-01 | 2019-02-12 |
| Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment - Opioid Use Disorder | Phase 3 | Completed | Braeburn Pharmaceuticals | 228 | 2015-11-01 | 2020-05-15 |
| Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) NTX/BUP, NTX/PBO-B, PBO-N/PBO-B - Opioid Use Disorder | Phase 3 | Completed | Alkermes, Inc. | 380 | 2015-08-01 | 2019-03-06 |
| Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder SUBOXONE sublingual film, RBP-6000 - Opioid Use Disorder, Opioid-related Disorders | Phase 3 | Completed | Indivior Inc. | 775 | 2015-07-27 | 2018-03-29 |
| Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study Extended Release Naltrexone, Treatment As usual - Opioid Use Disorder, Alcohol Use Disorder | Phase 3 | Completed | Oregon Health and Science University | 51 | 2014-06-01 | 2019-03-19 |
Opioid-Related Disorders (8) · Substance-Related Disorders (2) · Alcoholism (1) · Behavior, Addictive (1) · Chronic Pain (1) · Pregnancy Complications (1)
Chemically-Induced Disorders (8) · Mental Disorders (8) · Narcotic-Related Disorders (8) · Substance-Related Disorders (6) · Alcohol-Related Disorders (1) · Behavior (1) · Compulsive Behavior (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Impulsive Behavior (1) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urogenital Diseases (1)
Buprenorphine (3) · Buprenorphine, Naloxone Drug Combination (1) · Naltrexone (1) · Therapeutics (1) · vivitrol (1)
Alkermes, Inc. (2) · Indivior Inc. (2) · Braeburn Pharmaceuticals (1) · Oregon Health and Science University (1) · Stanford University (1) · Washington University School of Medicine (1)
United States (8) · Australia (1) · Canada (1) · Denmark (1) · Germany (1) · Hungary (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Maria A. Sullivan, MD, PhD (2) · Jeannie C Kelly, MD, MS (1) · Michael Frost, MD (1) · Philip T Korthuis, MD, MPH (1)
PMID 34752714, PMID 35287034, PMID 37657559, PMID 28061017, PMID 29674251, PMID 31013390, PMID 32777606, PMID 35137481, PMID 39122392, PMID 40342086
K24DA053564 (1), U10DA015815 (1)